ABSTRACT

CRIG POLYPEPTIDE FOR PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS

The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).

Figure 49